Related Experiment Video
Updated: Aug 7, 2026
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Multitargeted therapy: can promiscuity be praised in an era of political correctness?
Antonio Jimeno1, Manuel Hidalgo
1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA.
Abstract:
The rapidly expanding knowledge of the pathogenesis of cancer at the molecular level is providing new targets for drug discovery and development. However, cancer is a complex disease characterized by multiple genetic and molecular alterations affecting cell proliferation, survival, differentiation and invasion among others. Many of these alterations represent potential targets for the development of new anticancer therapeutics. Because of the enormous biological diversity of cancer, it is unlikely that attacking only one of these targets will eliminate a malignant cell. Rather, strategic combination of agents targeted against the most critical of those alterations will be needed. Another approach that is rendering promising clinical results is the use of more unspecific agents that inhibit or modulate several relevant targets simultaneously. A deep biologic understanding of the relative relevance of each target in different cancer types will be key to efficiently direct those drugs to diseases more likely to benefit from its particular modulation profile.
Insights
Targeted cancer therapies are advancing, but cancer
Area of Science:
- Oncology and Molecular Medicine
Background:
- Cancer pathogenesis is increasingly understood at the molecular level, revealing numerous potential therapeutic targets.
- Cancer's complexity, involving multiple genetic and molecular alterations, necessitates multifaceted treatment strategies.
Purpose of the Study:
- To explore the strategic development of novel anticancer therapeutics.
- To discuss the necessity of combination therapies or multi-target agents due to cancer's biological diversity.
Main Methods:
- Review of current knowledge on molecular cancer pathogenesis.
- Analysis of therapeutic strategies targeting molecular alterations.
- Consideration of combination therapies and multi-target agents.
Main Results:
- Attacking a single molecular target is unlikely to eradicate cancer cells.
- Combination therapies and agents modulating multiple targets show promise.
- Understanding target relevance across cancer types is crucial for effective drug development.
Conclusions:
- Effective cancer treatment requires targeting multiple critical molecular alterations.
- Developing drugs that modulate several targets simultaneously offers a promising therapeutic avenue.
- Personalized medicine approaches, informed by a deep understanding of cancer biology, are key to optimizing treatment outcomes.
Related Concept Videos
01:19Sedatives and Hypnotics Drugs: Benzodiazepines
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
01:28Drug Therapy
Antianxiety Medications
01:14CNS Depressants: Barbiturates and Benzodiazepines
01:23Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone